提醒

提醒專業圖表

Coya Therapeutics Inc. (COYA)

NasdaqCM: COYA · 即時價格 · USD

4.79

+0.12 (2.57%)

收盤時： Aug 14, 2026, 3:59 PM

4.79

+0.00%

盤後: 4:10 PM

2.57% (1D)

買價	n/a
市值	112.36M
營收 (ttm)	8.02M
淨利（ttm）	-21.67M
貝塔	n/a
EPS (ttm)	-1.07
本益比（ttm）	n/a
正向 PE	-2.78
P/B (ttm)	2.60
P/S (ttm)	14.01
Earnings Date	Nov 11, 2026

賣價	n/a
成交量	113,420
20 日平均成交量	196,448
打開	4.69
上一頁關閉	4.67
日間範圍	4.55 - 4.85
52 週範圍	3.71 - 7.75
分析師	n/a
目標價	15.5 (223.59%)
股利	n/a
Ex-股利日期	n/a

關於COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function ...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Dec 29, 2022

員工 8

證券交易所 NasdaqCM

股票代號 COYA

網站 https://www.coyatherapeutics.com

完整的公司簡介

財務表現

Coya Therapeutics 在 2025 年的營收為 7.95M，較前一年的 3.55M 增加 123.57%。淨利為 -21.23M，較前期增加 42.64%。

財務報表

分析師預測

根據7 分析師評等，COYA股票的平均評等為「null」。 12個月股價預測為15.5，與最新價格相比為上漲空間的223.59%。

股票預測

獲利驚喜

Coya Therapeutics 已於 Aug 11, 2026 公布季度財報：

營收的 $251.15K 錯過估計 $0, 與 -2.61% YoY 下降.

EPS 的 -0.28 超出估計 0.08, 與 22.22% YoY 成長.

下次財報發布

Coya Therapeutics Inc. 定於發布財報 Nov 11, 2026, 開市前。
分析師預估營收 ... 升級

新聞動態

1 月前 · Zacks

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

3 月前 · Pharmaceutical Technology

Coya Therapeutics secures FDA fast track status for COYA 302

COYA 302 is a proprietary biologic combination therapy that utilises a dual immunomodulatory approach.

3 月前 · Exec Edge

Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets i...

3 月前 · Exec Edge

NanoViricides to Participate at D. Boral Capital Global Conference in NYC

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s Presid...

3 月前 · Exec Edge

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven...

第 1 頁，共 2 頁

Coya Therapeutics Inc. (COYA)